Metraipolis › archive › dc_4e9f633b4e23

Analysis of Clinical Impact of CD33 rs12459419 Single-Nucleotide Polymorphism in AML Treated with Intensive Chemotherapy Without Gemtuzumab Ozogamicin — Europe PMC PMID:42123630

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42123630
DOI
10.3390/ijms27094050
License (as archived)
solo-consultazione
Archived
2026-11-03T01:18:52.692Z
SHA-256 of the archived text
e6d79314e6177c880461a913a4e3187d300230b81b0de4b309c836760400147a
Stable URL of this page
https://metraipolis.com/documento/dc_4e9f633b4e23

How to cite

Analysis of Clinical Impact of CD33 rs12459419 Single-Nucleotide Polymorphism in AML Treated with Intensive Chemotherapy Without Gemtuzumab Ozogamicin — Europe PMC PMID:42123630 — Europe PMC (en), https://europepmc.org/article/MED/42123630 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_4e9f633b4e23 (Metraipolis archive dc_4e9f633b4e23, sha256 e6d79314e6177c880461a913a4e3187d300230b81b0de4b309c836760400147a)
BibTeX
@misc{dc4e9f633b4e23,
  title = {Analysis of Clinical Impact of CD33 rs12459419 Single-Nucleotide Polymorphism in AML Treated with Intensive Chemotherapy Without Gemtuzumab Ozogamicin — Europe PMC PMID:42123630},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42123630},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_4e9f633b4e23; sha256 e6d79314e6177c880461a913a4e3187d300230b81b0de4b309c836760400147a},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42123630. Agents can read the archived copy with the MCP tool read_document.